Core Viewpoint - The stock of Zai Lab Limited (荃信生物-B) surged over 8% following the announcement of its long-acting dual antibody QX027N receiving clinical trial approval from the National Medical Products Administration, marking a significant advancement in the company's innovation pipeline for autoimmune and allergic diseases [1] Group 1: Clinical Developments - Zai Lab's QX027N injection is intended for the treatment of asthma and atopic dermatitis, indicating the company's commitment to addressing unmet medical needs in these areas [1] - The clinical trial approval signifies the official entry of the company's innovative dual antibody matrix into the clinical stage [1] Group 2: Strategic Partnerships - On October 28, Zai Lab announced a global exclusive collaboration and licensing agreement with Roche for its long-acting autoimmune dual antibody QX031N [1] - Under the agreement, Roche will gain exclusive rights for research, development, registration, production, and commercialization of QX031N globally [1] - Zai Lab will receive an upfront payment of $75 million, with potential milestone payments of up to $995 million, along with tiered royalties on future product sales [1]
荃信生物-B早盘涨超8% QX027N获得两项临床试验默示许可 拟用于治疗哮喘及特应性皮炎